Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Eli Lilly and Co. must be thinking: This is more like it.
The Indianapolis drugmaker today reported its second positive late-phase drug trial results in the past week.
The latest experimental drug to jump its hurdles is dulaglutide, a diabetes treatment that stimulates insulin production.
Dulaglutide met its main efficacy goals in three phase 3 trials that studied patients over 52 to 105 weeks, Lilly said.
Details of the trial results won?t be released until starting in 2013, but Lilly said dulaglutide performed better than three comparable drugs in efficacy.
http://www.indystar.com/article/201...-medicine-meets-goal-three-late-stage-studies
The Indianapolis drugmaker today reported its second positive late-phase drug trial results in the past week.
The latest experimental drug to jump its hurdles is dulaglutide, a diabetes treatment that stimulates insulin production.
Dulaglutide met its main efficacy goals in three phase 3 trials that studied patients over 52 to 105 weeks, Lilly said.
Details of the trial results won?t be released until starting in 2013, but Lilly said dulaglutide performed better than three comparable drugs in efficacy.
http://www.indystar.com/article/201...-medicine-meets-goal-three-late-stage-studies